Fig. 3: AKS-452 immunogenicity: mutant SP/RBD IgG titers. | npj Vaccines

Fig. 3: AKS-452 immunogenicity: mutant SP/RBD IgG titers.

From: Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine

Fig. 3

Serum samples were obtained from 67 subjects on days 0, 28, 56, 90, 180, and 273 after receiving a 90 µg s.c. dose of AKS-452 ≥ 3 months after completing regimens of regulatory–approved vaccines and assessed for IgG binding titers against different mutant SP/RBD antigens via ELISA (a, dotted red lines are references of day 0 and day 28 WT means) and presented as fold-change per subject (b; dotted black line denotes a 2-fold change). a All day-28, -56, and -90 mean values (p < 0.0001) and some day-180 values (*, p < 0.05) were significantly different from respective day-0 mean values (t Test equal variance, one-tailed). b All geometric mean values of the fold-change response on day 28, 56, 90, 180, and 273 were significantly greater than 2.0 (p < 0.05), except those designated not significant (n.s.). The mean ± s.e.m. are shown in each panel.

Back to article page